• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

    11/20/24 7:00:00 AM ET
    $EXAI
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXAI alert in real time by email
    • Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs
    • Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery
    • Recursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube

    SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (NASDAQ:EXAI) ceased trading and will be delisted from Nasdaq.

    "I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. "With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology."

    "The combination of our platforms and people make us the company to beat," said David Hallett, Ph.D., former CSO and Interim CEO of Exscientia and newly appointed Chief Scientific Officer at Recursion. "With our combined strength of real-world proprietary data and the models we've created – hypothesizing, testing and learning in a continuous loop – we're redefining the space by shrinking timelines and costs, identifying and optimizing lead candidates faster than traditional methods."

    The Company is pleased to share updates on the combined entity's pipeline, partnerships, and platform below:

    Pipeline

    The combined pipeline represents more than 10 clinical and preclinical programs. In addition there are approximately 10 advanced discovery programs in the current pipeline.

    Updated guidance is bulleted below as well as a snapshot of our pipeline:

    • REC-617 (CDK7 inhibitor; Advanced Solid Tumors): Initial Phase 1 monotherapy safety and PK/PD data expected at the AACR Special Conference on December 9th 2024, and a webinar to follow on December 10th 2024.
    • REV102 (ENPP1 inhibitor; Hypophosphatasia): Development candidate nomination expected in Q4 2024
    • REC-4881 (MEK1/2 inhibitor, Familial Adenomatous Polyposis): Phase 1b/2 safety and early efficacy data expected in H1 2025
    • REC-2282 (pan-HDAC inhibitor; Neurofibromatosis Type 2): PFS6 futility analysis expected by H1 2025
    • REC-3565 (MALT1 inhibitor, B-Cell Malignancies): Phase 1 first patient dosed (FPD) expected in Q1 2025
    • REC-4539 (LSD1 inhibitor, Small-Cell Lung Cancer): Phase 1 first patient dosed (FPD) expected in H1 2025
    • REC-994 (Superoxide scavenger, Cerebral Cavernous Malformation): Further data to be shared at an upcoming medical conference / publication / webinar in H1 2025; regulatory update expected by H2 2025
    • REC-394 (C. difficile Toxin B selective inhibitor, C. difficile): Phase 2 update expected in Q1 2026
    • REC-1245 (RBM39 degrader; Solid Tumors and Lymphoma): Phase 1 dose-escalation data update expected in H1 2026
    • REC-4209 (undisclosed target; Idiopathic Pulmonary Fibrosis): IND-enabling studies are ongoing
    • REC-4881 in APC/AXIN1 indications have been deprioritized as part of a disciplined strategic prioritization of the portfolio. Study status will be updated on clinicaltrials.gov

    Recursion's Pipeline of Programs

    Partnerships

    The combined company's therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology. The combined company has received approximately $450M in upfront and milestone payments from partnerships to date. Through these partnerships, we have the potential to receive more than approximately $20B in additional milestone payments before royalties.

    Recursion's Partnership

    Platform

    With chemical design and synthesis methods from Exscientia and over 60 petabytes of proprietary data generated in house or licensed from partners like Helix and Tempus, the combined entity will strengthen the Recursion OS to be a first-in-class and best-in-class drug discovery and development platform.

    Recursion Model2

    The platform will continue to drive iterative loops of hypotheses and active learning all the way from research to development, with the goal of eventually creating virtual cells that will allow the company to execute clinical trials at scale.

    Company, Board, and Leadership Updates

    The combined company will have approximately 800 employees with the headquarters remaining in Salt Lake City, and primary offices in Toronto, Montreal, Milpitas, New York, the Oxford area, and London.

    Individual board and executive leadership changes of Recursion, effective as of November 20, 2024, are summarized below:

    • Franziska Michor, a former member of the Board of Directors of Exscientia, was appointed as a Class II Director of the Board of Directors of Recursion, with her initial term to extend until the 2026 Annual Meeting of Stockholders of Recursion.
    • Ben Taylor, former Chief Financial and Strategy Officer of Exscientia, was appointed as the Chief Financial Officer of the Company and President of Recursion UK.
    • Dave Hallett, former Interim Chief Executive Officer of Exscientia, was appointed as Chief Scientific Officer of the Company.
    • Kristen Rushton, Chief Business Operations Officer of the Company, was promoted to Chief Operating Officer of the Company.
    • Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives of the Company was promoted to serve as Chief Business Officer of the Company.
    • Lina Nilsson, Senior Vice President, Emerging Technologies of the Company, was promoted to serve on the executive team as Senior Vice President, Head of Platform of the Company.
    • Michael Secora, Tina Marriott, and Laura Schaevitz will transition from their executive roles into advisor roles for the combined company. All three have provided many years of dedicated service to the Company and we wish to express our heartfelt gratitude for each of them. Recursion would not be where it is today without their dedication and efforts.

    Update Call Information

    Recursion will host an update call today at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT. The Company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts, and on Exscientia's LinkedIn account. Questions can be submitted via this link ahead of time or during the livestream.

    About Recursion

    Recursion is a leading, clinical-stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

    Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has other primary offices in Toronto, Montreal, the San Francisco Bay Area, New York, the Oxford area, and London.

    Recursion Investor Relations

    [email protected]

    Recursion Media

    [email protected]

    Forward Looking Statements

    Statements contained herein which are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statements regarding the leadership position of the combined company and its impact on the industry; the ability for the combined business to accelerate the discovery of better solutions for patients; the timing of IND submissions and IND enabling studies; the potential to receive upfront, milestone, and royalty payments and work on over 60 therapeutic programs; the strengthening of the Recursion OS through the combined company; the continued learning of Recursion's platform and the creation of virtual cells to enable execution of clinical trials at scale; Recursion's achievement of efficiencies; the continuous expansion of the Recursion OS datasets; and advancing the future of medicine; the outlook for Recursion's future business and financial performance; and others. Such forward-looking statements are based on the current beliefs of Recursion's management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward-looking statements based on a variety of risks and uncertainties including: the ability of the combined company to retain key personnel; the ability to realize the benefits of the combination, including cost synergies; the ability to successfully integrate Exscientia's business with Recursion's business, at all or in a timely manner; the amount of the costs, fees, expenses and charges related to the combination; the effect of economic, market or business conditions, including competition, regulatory approvals and commercializing drug candidates, or changes in such conditions, have on the combined company's operations, revenue, cash flow, operating expenses, employee hiring and retention, relationships with business partners, the development or launch of technology enabled drug discovery, and commercializing drug candidates; the risks of conducting business internationally; the impact of changes in interest rates by the Federal Reserve and other central banks; the impact of potential inflation, volatility in foreign currency exchange rates and supply chain disruptions; the ability to maintain technology-enabled drug discovery in the biopharma industry; and risks relating to the market value of Recursion's Class A common stock.

    Other important factors and information are contained in Recursion's most recent Annual Report on Form 10-K, including the risks summarized in the section entitled "Risk Factors," Recursion's subsequent Quarterly Reports on Form 10-Q, the joint definitive proxy statement filed by Recursion and Exscientia on October 10, 2024, as amended by the supplemental disclosures filed by Recursion on November 6, 2024, and each of Recursion's other filings with the U.S. Securities and Exchange Commission (the "SEC"), which can be accessed at https://ir.recursion.com, or www.sec.gov. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. Recursion undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Photos accompanying this announcement are available at

    https://www.globenewswire.com/NewsRoom/AttachmentNg/359d7cd4-0ccf-4210-938d-f585a9b073ee

    https://www.globenewswire.com/NewsRoom/AttachmentNg/a94dc301-518d-48a8-b8d3-430cd726d651

    https://www.globenewswire.com/NewsRoom/AttachmentNg/57cb9454-a7a7-4abf-a76f-82356a3682ac



    Primary Logo

    Get the next $EXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What is the main goal of the business combination between Recursion and Exscientia?

      The business combination of Recursion and Exscientia aimed to create a vertically-integrated platform for drug discovery, leveraging AI technologies to enhance efficiency in finding novel drug candidates.

    • How does Recursion plan to improve drug discovery through its new platform?

      Recursion's new platform aims to reduce the time and cost of drug discovery significantly while focusing on first and best-in-class drug development.

    • What does Recursion's clinical and preclinical pipeline look like after the combination with Exscientia?

      The combined entity's pipeline includes over 10 clinical and preclinical programs and more than 10 partnered programs, indicating a robust pipeline for potential drug candidates.

    • What financial benefits has Recursion achieved from its partnerships so far?

      Recursion has received approximately $450M in upfront and milestone payments and has the potential for over $20B in additional payments from its partnerships.

    • When will Recursion provide an update on its operations, and through what platforms can investors access this information?

      Recursion will host an update call on November 20, 2024, at 7:30 a.m. ET, where they will share more details on the combined pipeline and strategies moving forward.

    Recent Analyst Ratings for
    $EXAI
    $RXRX

    CompanyDatePrice TargetRatingAnalyst
    Exscientia Plc
    $EXAI
    7/9/2024Buy
    TD Cowen
    Exscientia Plc
    $EXAI
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    Recursion Pharmaceuticals Inc.
    $RXRX
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    Recursion Pharmaceuticals Inc.
    $RXRX
    3/16/2023$17.00Buy
    Needham
    Recursion Pharmaceuticals Inc.
    $RXRX
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    Recursion Pharmaceuticals Inc.
    $RXRX
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    Recursion Pharmaceuticals Inc.
    $RXRX
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    Recursion Pharmaceuticals Inc.
    $RXRX
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $EXAI
    $RXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Altitude Lab Startups Raise $154M in Capital

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

      2/18/25 11:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

      Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor

      1/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Exscientia plc

      TD Cowen initiated coverage of Exscientia plc with a rating of Buy

      7/9/24 7:31:11 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia plc downgraded by BofA Securities with a new price target

      BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously

      1/5/24 7:41:29 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

      5/22/23 7:50:41 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RXRX
    SEC Filings

    See more
    • SEC Form S-8 filed by Recursion Pharmaceuticals Inc.

      S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:07:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.

      10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:02:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:01:30 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EXAI
    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.  About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the

      5/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

      Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful synergies and streamlined operations while maintaining capabilities, resulting in cash runway until mid 2027 SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a le

      5/5/25 6:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

      In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.The early safety profile of REC-4881 was generally consistent with that of prior MEK1/2 inhibitors; among 19 patients across Phase 1b and 2, most treatment-related adverse events were Grade 1 or 2, with Grade 3 events in 16% of patients and no Grade ≥4

      5/4/25 12:45:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exscientia Plc

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      11/22/24 9:11:55 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exscientia Plc

      SC 13D/A - Exscientia plc (0001865408) (Subject)

      11/22/24 8:00:16 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RXRX
    Financials

    Live finance-specific insights

    See more
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

      Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit

      2/24/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

      REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --

      12/9/24 6:00:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 26,571 shares, decreasing direct ownership by 3% to 842,099 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:38:14 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Li Dean Y was granted 2,268 shares, increasing direct ownership by 3% to 79,618 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:52 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Dar Zavain was granted 2,745 shares, increasing direct ownership by 3% to 110,877 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:01 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care